- Eli Lilly dominates first-half biotech acquisitions, with no sign of slowing downRiding on its trillion-dollar heft and successes in treating obesity, Eli Lilly has now become a force in one area where it hasn’t historically been the main player: M&A. The Indianapolis-bas…Endpoints · 18d ago↗ source
- Catalent to divest UK site; Rottendorf, Evonik announce manufacturing buildsPlus, news about RoslinCT, Novo Nordisk and more. 🇬🇧 Catalent to sell UK site to Codis: The CDMO is set to take Catalent’s oral solid dose factory in Nottingham, with ...Endpoints · 18d ago↗ source
- HHS plan to speed drug research won’t remove ‘self-inflicted’ delays<figure><div><img src="https://imgproxy.divecdn.com/CBRbv7ysPGDg2gR4-a3jhbQNYceSmw-Eq03sjZFRhY4/g:ce/rs:fill:1600:900:1/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9HZXR0eUltYWdlcy0xMTk2ODIwNDM5LmpwZ…